Tryptamine Therapeutics (ASX:TYP) ROE % Adjusted to Book Value : -51.46% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Tryptamine Therapeutics ROE % Adjusted to Book Value?

Tryptamine Therapeutics's ROE % for the quarter that ended in Dec. 2023 was -94.18%. Tryptamine Therapeutics's PB Ratio for the quarter that ended in Dec. 2023 was 1.83. Tryptamine Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -51.46%.

Tryptamine Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Tryptamine Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics ROE % Adjusted to Book Value Chart

Tryptamine Therapeutics Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-5.80

-21.83

-15.22

-31.41

-126.71

Tryptamine Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial						-13.89	-21.49	-62.62	-146.15	-51.46

Competitive Comparison of Tryptamine Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Tryptamine Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tryptamine Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tryptamine Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Tryptamine Therapeutics's ROE % Adjusted to Book Value falls into.

Tryptamine Therapeutics ROE % Adjusted to Book Value Calculation

Tryptamine Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-110.24%	/	0.87
	=	-126.71%

Tryptamine Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-94.18%	/	1.83
	=	-51.46%

Tryptamine Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Tryptamine Therapeutics (ASX:TYP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

697 Burke Road, Suite 201, Camberwell, VIC, AUS, 3124

Website

https://www.exopharm.com

Exopharm Ltd is a biopharmaceutical company that engages in the development of regenerative medicine in Australia. The company is engaged in developing and commercializing exosomes as therapeutic agents. The company operates in one segment namely the research and development of biopharmaceutical drugs. Revenue is generated from Australia.

Tryptamine Therapeutics (ASX:TYP) Headlines

No Headlines